Home > Healthcare > Drug Device Combination > Therapeutic Systems > Overactive Bladder Treatment Market

Overactive Bladder Treatment Market Share

Report ID: GMI9699
Published Date: May 2024
Report Format: PDF

Download Free Sample

Overactive Bladder Treatment Market Share

The overactive bladder treatment industry is highly competitive, including prominent pharmaceutical companies and emerging biotech companies. Key players in the market are offering effective drugs such as anticholinergics and beta-3 adrenergic agonists. Innovations in minimally invasive treatments, such as botox injections by Allergan and neuromodulation therapies by Medtronic, have further intensified competition.

Overactive Bladder Treatment Market Companies

Few of the prominent players operating in the industry include:

AbbVie Inc.
Astellas Pharma Inc.
Axonics, Inc.
BlueWind Medical
Cipla Ltd.
Endo International plc
Laborie
Lupin Ltd.
Medtronic plc
Merck & Co.
Pfizer, Inc
Sumitomo Pharma America, Inc (Urovant Sciences.)
Teva Pharmaceutical Industries Ltd.
Viatris Inc.
Zydus Lifesciences Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global industry size for overactive bladder treatment was valued at USD 3.5 billion in 2023 and is anticipated to register 4.3% CAGR between 2024 and 2032 due to rising prevalence of overactive bladder and increasing research investments and activities.

The drug therapy segment in the overactive bladder treatment market held 48.9% revenue share in 2023 as drug therapies are widely prescribed due to their efficacy in managing overactive bladder symptoms and increasing regulatory support.

Asia Pacific market size is expected to record 4.7% CAGR between 2024 and 2032 due to the rising healthcare infrastructure development and increasing awareness about urinary disorders.

AbbVie Inc., Astellas Pharma Inc., Axonics, Inc., BlueWind Medical, Cipla Ltd., Endo International plc, Laborie, Lupin Ltd., Medtronic plc, Merck & Co., and Pfizer, Inc, among others.